June 4, 2024
CellCarta offers a full range of validated proteomic assays. With sites accredited by CAP and CLIA certifications, we provide the highest standard of quality. Our team of experts will guide and customize multiplexed assays to meet clinical trial needs, recommending the most appropriate path to validate assays, single plex and mutliplex.
Contact us for any custom development or assay validation.
You might also be interested by
Scientific Publications
A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors
October 20, 2025
More infoPress Releases
Lunit, CellCarta Announce Global Alliance to Expand Access to Digital Pathology AI for Clinical Trials
September 24, 2025
More infoCellTalk Blog
B-Cell Populations in Focus: A New Flow Cytometry Assay for Increased Sensitivity in Autoimmune Research
September 19, 2025
Flow Cytometry
More infoCellTalk Blog
Next-Gen Immune Monitoring: The Value of Single-Cell Sequencing
August 12, 2025
More info